Everolimus is a Medicine belongs to Immunosuppressants group whose information about Brand can be referenced from   Book : Martindale    Page : 1959   Edition : 38,

  ►   Brandname : Certican, Afinitor, Zortress

  ►  Strength : with   ,

Reference of this Medicine for its Strength can be taken from   Book :    Page :    Edition : ,
A Route of administration in pharmacology and toxicology is the path by which a drug, fluid, poison, or other substance is taken into the body. Routes of administration are generally classified by the location at which the substance is applied. Common examples include oral and intravenous administration.

  ►  Route of administration : Oral,
Reference :-   Book : Martindale    Page : 1958   Edition : 38,

Dosing of Medicine differ in Adult & Pediatrics ↓


Adult Dose

S.No Ailment   Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency   Additional Info
1 For immunosuppression in heart or kidney transplantation Oral 750 Microgram b.d. It is begun as soon as possible after transplantation, and given at the same time as ciclosporin.
2 Liver transplantation Oral 1 mg b.d. It is begun about 4 weeks after transplantation, and given at the same time of day as tacrolimus.
3 In advanced renal cell carcinoma, advanced breast cancer, advanced neuroendocrine tumours, and renal angiomyolipoma Oral 10 mg o.d. And if toxicity occurs, the dose may be reduced to 5 mg OD, or withheld and restarted at 5 mg OD.
4 Subependymal giant-cell astrocytoma associated with tuberous sclerosis in patients who are unable to have surgery Oral o.d. The doses are based on the body-surface. For patient up to 1.2 m2; given 2.5 mg. And 1.3 to 2.1 m2; given 5 mg. And for body surface 2.2 m2 or over; given 7.5 mg.

Ref :-  Book : Martindale    Page : 1958   Edition : 38,




Pediatric Dose

S.No Ailment   Age Min   Age Max   Weight ( Kg ) Route   Dose Min   Dose Max   Unit   Dosage Form   Frequency  Additional Info  
1 Subependymal giant-cell astrocytoma associated with tuberous sclerosis in patients who are unable to have surgery 3 Year and above 3 Year Oral o.d.

Ref :- Book : Martindale    Page : 1958   Edition : 38,
►  Side Effect : Common adverse effects:, anaemia, thrombocytopenia, arthralgia, asthenia, headache, hypersensitivity reactions, angioedema, hyperlipidaemia, renal toxicity, Serious adverse effects are, hypertension, peripheral oedema, infections, lymphoma, interstitial lung disease, thrombotic microangiopathy,
Ref :-   Book : Principle of Pharmacology (The Pathophysiologic Basis of Drug Therapy)    Page : 804   Edition : 3,

►  Drug Interaction : Drug interaction of Everolimus is with , Live Vaccines,  Cyclosporine , Ketoconazole , Erythromycin , Verapamil ,
Ref :-   Book : Martindale    Page : 1959   Edition : 38,


  ►    Mechanism of Drug Drug Interaction :  Everolimus is a substrate of cytochrome P450 isoenzyme CYP3A4 and a substrate and moderate inhibitor of P-glycoprotein. Plasma concentrations of everolimus may be affected by inducers or competitive inhibitors of CYP3A4 or P-glycoprotein. Exposure to everolimus is increased when given with the CYP3A4/P-glycoprotein inhibitors ciclosporin, ketoconazole, erythromycin, and verapamil. Substances that are potent inducers of CYP3A4 or P-glycoprotein may decrease exposure to everolimus: dosage increases have been suggested if use together cannot be avoided. In vitro results suggest that systemic concentrations of everolimus after usual oral doses are unlikely to inhibit P-glycoprotein, CYP3A4, or CYP2D6, but theoretically, everolimus may affect the bioavailability of CYP3A4 or P-glycoprotein substrates when given together. Use with live vaccines should be avoided.,
Ref :-   Book : Martindale    Page : 1959   Edition : 38,


►  Contraindication : Excess mortality, graft loss, and hepatic artery thrombosis has been associated with the use of sirolimus in immunosuppressive regimens in liver transplant recipients and therefore not used in such patients.,
Ref :-   Book : Martindale    Page : 1959,1967   Edition : 38,
  ►  Mechanism of Action :   Everolimus is a derivative of sirolimus, it is used as a proliferation signal inhibitor in the prevention of graft rejection episodes in patients undergoing heart or kidney transplantation as part of an immunosuppressive regimen.,
Ref :-   Book : Martindale    Page : 1958   Edition : 38,

Pathway of Dietry Product


​   ► Act.Comp / Nutrient / Food / Herb as follows :- Vinca with Another pathway,

  ►  Pathway with its reference as follows :-
  • Anticancer effect . --- (PDR for Herbal medicines. (2000) (4th ed.). U.S. )

  •   ►  URL -- http://www.travolekar.ru/arch/Pdr_for_Herbal_Medicines.pdf,


    Dietry Substance Interactions


    ​   ► This Medicine interact with :- NA



    ContraIndication Dietry Substance


    ​   ► This Medicine contraindicate with :- NA

    ►   Route of Elimination :   NA


    ►    Plasma Half-life :
      Min value :-   Mean elimination half life; about 30 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 1958   Edition : 38,

    ►    Peak Plasma Concentration :   Min value :-   about 1 to 2 hours,    Max value :-   NA
    Ref :-   Book : Martindale    Page : 1958   Edition : 38,